{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-002685","form_type":"8-K","ticker":"XLO","cik":"0001840233","company_name":"Xilio Therapeutics, Inc.","filed_at":"2023-03-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.033678+00:00","generated_at":"2026-06-18T16:06:19.403072+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Xilio reports FY2022 net loss $88.2M; cash $120.4M; XTX202 shows early tumor-selective activation","bullets":["Cash and cash equivalents $120.4M as of Dec 31, 2022, down from $198.1M; cash runway into Q2 2024.","Net loss for FY2022 was $88.2M vs $75.8M in 2021; Q4 net loss $22.5M vs $19.7M.","XTX202 (tumor-activated IL-2) showed preliminary pharmacodynamic evidence of tumor-selective activation in two patients; no vascular leak syndrome observed.","XTX202 Phase 2 monotherapy trial in melanoma and RCC to initiate April 2023; preliminary Phase 1/2 data expected Q3 2023.","XTX101 (anti-CTLA-4) RP2D set at 150 mg Q6W; preliminary Phase 1 data expected Q2 2023; exploring partnership."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-002685","json":"https://secwatch.observer/filing/0001558370-23-002685.json","markdown":"https://secwatch.observer/filing/0001558370-23-002685.md","text":"https://secwatch.observer/filing/0001558370-23-002685.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840233/000155837023002685/0001558370-23-002685-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840233/000155837023002685/xlo-20230302x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T16:06:19.403072+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"632026996df838f78ae61596a283a49ad677f0b9","claim":"Xilio Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2022.","evidence_excerpt":"On March 2, 2023, Xilio Therapeutics, Inc. (the “Company”) announced its financial results for the quarter and year ended December 31, 2022 and other business highlights.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840233/000155837023002685/0001558370-23-002685-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}